Coding Analysis for Labs (CAL) Tracking Sheet

Prothrombin Time (Addition of ICD-9-CM 289.81, Primary Hypercoagulable State as a Covered Indication)

CAG-00328N

Issue

CMS received an external request to add Primary hypercoagulable state, ICD-9-CM 289.81, to the covered indication code list for the Prothrombin Time (PT) NCD at 190.17 of the NCD Manual.

ICD-9-CM 289.81 was created after the development of the ICD-9-CM Codes Covered By Medicare list for the PT NCD, and is not included in the current list. The narrative covered indications for the PT NCD include hypercoagulable state.

Consequently, we believe code 289.81, Primary hypercoagulable state, flows from the narrative. We are seeking public comment on the addition of code 289.81 to the ICD-9-CM Codes Covered By Medicare

The regulation for maintaining code lists in the negotiated NCDs for clinical diagnostic laboratory services states that codes on the covered list flow from the existing NCD narratives of covered indication. The regulation was published February 25, 2005 in the Federal Register, Vol.70, No. 37 and can be viewed at http://www.cms.hhs.gov/Medicare/Coverage/CoverageGenInfo/LabNCDsICD10.html#TopOfPage.

National Coverage Determinations

Benefit Category

Diagnostic Laboratory Tests

Requestor Information

Requestor Name Requestor Letter
Debbie Beedlow, CMC, Hematology and Oncology Consultants View Letter
N/A

Important Dates

Formal Request Accepted and Review Initiated
04/18/2006
Expected CAL Completion Date
07/18/2006
Public Comment Period
04/18/2006 - 05/18/2006
Proposed Decision Memo Due Date
Proposed Decision Memo Released
Proposed Decision Memo Public Comment Period
Decision Memo Released
05/31/2006
Comments for this CAL
View Public Comments

Contacts

Lead Analysts
Maria Ciccanti
Lead Medical Officers
James Rollins, MD, MSHA, PhD

Medicare Benefit Category Determination Date

Actions Taken

April 18, 2006

CMS accepts a request to add ICD-9-CM code 289.81 as a covered indication in the Prothrombin Time national coverage determination list of covered indications.

The 30-day public comment period begins with this date, and ends after 30 calendar days. CMS considers all public comments, and is particularly interested in clinical studies and other scientific information relevant to the test under consideration.

May 31, 2006

Posted decision memo.